Aims and objectives

The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Their mission includes: 

  • Developing microbiological guidelines and supporting the clinical use of phages and phage-derived products, via clinical trials and compassionate use
  • Identifying bacterial pathogens and infectious disease indications where non-traditional antibacterials, including bacteriophage therapies, may lead to cure or improved clinical outcomes
  • Increasing knowledge and fostering research on phage-derived enzymes, especially lysins, to identify the optimal carriers and applications in clinical settings, such as gels and nanoparticles
  • Creating a network and promoting the establishment of academic phage therapy centres across European countries, based on the models developed in Belgium, France, Israel, Australia, and the USA

Activities and resources

ESGNTA Newsletter, December 2025

Download


ESGNTA Newsletter, July 2025

Download


ESGNTA Newsletter, March 2025

Download

Cross-border dialogue: An international survey of regulators on phage therapy. 

Alvarez RD, Årdal C, Classen AY, Nagel TE, Ceyssens PJ, German GJ. Int J Antimicrob Agents. 2025 Dec;66(6):107614

Go to publication


Phage therapy.

Mikael Skurnik, Sivan Alkalay-Oren, Maarten Boon, Martha Clokie, Thomas Sicheritz-Pontén,Krystyna Dąbrowska, Graham F. Hatfull, Ronen Hazan, Matti Jalasvuori, Saija Kiljunen, Rob Lavigne, Danish J. Malik, Ran Nir-Paz & Jean-Paul Pirnay. Nature Reviews Methods Primers 2025.  5, Article number: 10

Go to publication


2025 ICM: Role of Unconventional Medications. 

Suh GA; ESGNTA; Scobie A; ESGNTA; Piuzzi NS, Bartak V, Anyaehie UE, Arciola CR, Batailler C, Benes M, Binlaksar R, Buttaro M, Damioli LE, de Beaubien BC, Dietz MJ, Doub JB, Elmenawi KA, Falez F, Ferry T; ESGNTA; Goswami K, Kucukdurmaz F, Li B, Metsemakers WJ, Moriarty TF, Saeed M, Shah RP, Springer B, Tootsi K, Tsiridis E, Urish KL. J Arthroplasty. 2025 Oct 31:S0883-5403(25)01395-6

Go to publication


Phages and phage-borne enzymes as new antibacterial agents. 

McCallin S, Drulis-Kawa Z, Ferry T, Pirnay JP, Nir-Paz R. Clin Microbiol Infect. 2023;20:S1198-743X(23)00528-1.

Go to publication


Personalized Phage Therapy: Basic Principles of monitoring and treatment: Supplement 5 1 Nov 2023 

Nir-Paz R, Iredell J, Suh G, Fabijan AP. Clinical Infectious Diseases, Vol 77, Issue Supplement 5, 1 November 2023.

Go to publication

Executive Committee

  Ran Nir-Paz

Ran Nir-Paz

Chair
Hadassah-Hebrew University Medical Center. Clinical Microbiology and infectious Diseases
Jerusalem, Israel
  Tristan Ferry

Tristan Ferry

Education Officer
Hospices Civils de Lyon. Infectious Diseases
Lyon, France
  Jean-Paul Pirnay

Jean-Paul Pirnay

Science Officer
Queen Astrid Military Hospital. LabMCT
Brussels, Belgium
  Gina Suh

Gina Suh

Secretary
Mayo Clinic
Rochester, United States
  Zuzanna Drulis-Kawa

Zuzanna Drulis-Kawa

Treasurer
University of Wroclaw. Department of Pathogen Biology and Immunology
Wroclaw

Contact

If you have questions or comments for our study group, we warmly invite you to contact us!

Contact form